Document:

Registration Rights Agreement (Credit Agreement) dated as of March 31, 2010

 Exhibit 10.10 
 REGISTRATION RIGHTS AGREEMENT 
 This REGISTRATION
RIGHTS AGREEMENT, dated as of March 31, 2010 (this “Agreement”), is made by and among Flotek Industries, Inc., a Delaware corporation, with headquarters located at 2930 W. Sam Houston Parkway North, Suite 300, Houston, Texas
77043 (the “Company”), and the investors named on the signature pages hereto (the “Investors”). 
 RECITALS: 
 A. Pursuant to the Amended and Restated Credit Agreement dated as of the date hereof (the
“Credit Agreement”) by and among the Company, as Borrower, the Investors, as Lenders, and Whitebox Advisors LLC, as Administrative Agent, the Company has agreed, upon the terms and subject to the conditions of the Credit Agreement,
to issue to the Investors shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as a commitment fee (the “Commitment Shares”). 
 B. Pursuant to the Credit Agreement, the Company may, subject to the terms and conditions of the Credit Agreement, be required to issues to
the Investors shares of Common Stock as repayment of the principal of the Notes (the “Payment Shares”). 
 C.
In order to induce the Investors to execute and deliver the Credit Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended (the “Securities Act”) and applicable state
securities laws with respect to the Common Shares (as hereinafter defined). 
 In consideration of the premises and the mutual
covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Capitalized terms used and not otherwise defined herein have the respective meanings given them set forth in the Credit Agreement. In
addition, as used in this Agreement, the following terms have the following meanings: 
 1.1 “Commitment Share
Registration Period” means the period between the date of the Credit Agreement and the earlier of (i) the date on which all of the Commitment Shares have been sold under a Registration Statement, or (ii) the date on which all of
the Commitment Shares (in the opinion of the Investors’ counsel) may be immediately sold without registration and without restriction (including without limitation as to volume by each holder thereof) as to the number of the Commitment Shares
to be sold, pursuant to Rule 144 or otherwise. 
 1.2 “Exchange Act” means the Securities Exchange Act of
1934, as amended. 
 1.3 “FINRA” means the Financial Industry Regulatory Authority, Inc. 

 1.4 “Investors” means the investors named on the signature pages hereto and
any of their transferees or assignees who agree to become bound by the provisions of this Agreement in accordance with Article IX hereof. 
 1.5 “National Securities Exchange” means any national securities exchange under Section 12(b) of the Exchange Act. 
 1.6 “OTC Bulletin Board” means the OTC Bulletin Board service of broker-dealers admitted the membership in FINRA and their
associated person. 
 1.7 “Payment Share Registration Period” means the period between the date of the issuance
of any Payment Shares and the earlier of (i) the date on which all of such Payment Shares have been sold under a Registration Statement, or (ii) the date on which all of such Payment Shares (in the opinion of the Investors’ counsel)
may be immediately sold without registration and without restriction (including without limitation as to volume by each holder thereof) as to the number of such Payment Shares to be sold, pursuant to Rule 144 or otherwise. 
 1.8 “Registrable Securities” Commitment Shares and the Payments Shares. 
 1.9 “Registration Period” means the Commitment Registration Period or a Payment Registration Period, as the case may be.

 1.10 “Registration Statement” means a Registration Statement of the Company filed under the Securities Act.

 1.11 “Required Filing Date” means the Commitment Required Filing Date (as defined below) or a Payment
Required Filing Date (as defined below), as the case may be. 
 1.11 The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing a Registration Statement or statements in compliance with the Securities Act and pursuant to Rule 415 and the
declaration or ordering of effectiveness of such Registration Statement by the SEC. 
 1.12 “Rule 415” means
Rule 415 under the Securities Act, or any successor Rule providing for offering securities on a continuous basis, and applicable rules and regulations thereunder. 
 1.13 “SEC” means the United States Securities and Exchange Commission. 
 ARTICLE II 
 REGISTRATION 
 2.1 Mandatory Registration. 
 (a) The Company will file with the SEC a
Registration Statement on Form S-3 registering the Commitment Shares and no securities other than additional securities held by Investors for resale within 30 days after the date of the Credit Agreement (the “Commitment

  

 2 

 
Required Filing Date”). If Form S-3 is not available at that time, then the Company will file a Registration Statement on such form as is then available to effect a registration of the
Commitment Shares by such date, subject to the consent of the Investors, which consent will not be unreasonably withheld. 
 (b)
The Company will file with the SEC a Registration Statement on Form S-3 registering the Payment Shares and no securities other than additional securities held by Investors for resale within 30 days after the date of each issuance of Payment Shares
(each such date a “Payment Required Filing Date”). If Form S-3 is not available at that time, then the Company will file a Registration Statement on such form as is then available to effect a registration of the Payment Shares by
such date, subject to the consent of the Investors, which consent will not be unreasonably withheld. 
 (c) To the extent
allowable under the Securities Act and the rules promulgated thereunder (including Rule 416 under the Securities Act), each Registration Statement will include the Registrable Securities covered by such Registration Statement and such
indeterminate number of additional shares of Common Stock as may become issuable to prevent dilution resulting from stock splits, stock dividends or similar transactions. 
 (d) Notwithstanding anything to the contrary contained in this Agreement, but subject to the payment of the Late Payments pursuant to Section 2.4 hereof, if the staff of the SEC (the
“Staff”) or the SEC seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities by or on behalf of the Company, or in any other manner,
such that the Staff or the SEC do not permit such Registration Statement to become effective and used for resales in a manner that does not constitute such an offering and that permits the continuous resale at the market by the
Investors participating therein (or as otherwise may be acceptable to each Investor) without being named therein as “underwriters,” then the Company shall reduce the amount of Registrable Securities to be included in such
Registration Statement by all Investors to such amount as the Staff and the SEC will permit for such Registration Statement to become effective without such Investors being so named. In making such reduction, the Company shall reduce the
amount of Registrable Securities to be included by all Investors on a pro rata basis (based upon the number of Registrable Securities otherwise required to be included for each Investor) unless the inclusion of Registrable Securities by a particular
Investor or a particular set of Investors are resulting in the Staff or the SEC’s “by or on behalf of the Company” offering position, in which event the Registrable Securities held by such Investor or set of Investors shall be
the only Registrable Securities subject to reduction (and if by a set of Investors on a pro rata basis by such Investors or on such other basis as would result in the exclusion of the least amount of Registrable Securities by all such
Investors). In addition, if the Staff or the SEC requires any Investor seeking to sell Registrable Securities under a Registration Statement filed pursuant to this Agreement to be specifically identified as
an “underwriter” in order to permit such Registration Statement to become effective, and such Investor does not consent to being so named in such Registration Statement, then, in each such case, the Company shall reduce
the total amount of Registrable Securities to be registered on behalf of such Investor, to such amount as the Staff or the SEC will permit without requiring such identification. In the event of any reduction in Registrable
Securities pursuant to this paragraph, an affected Investor shall have the right to require, upon

  

 3 

 
delivery of a written request to the Company signed by such Investor, the Company to file a Registration Statement within 30 days of such request (subject to any restrictions imposed by Rule 415
or required by the Staff or the SEC) for resale of Registrable Securities by such Investor in a manner reasonably acceptable to such Investor, and the Company shall following such request cause to be and keep effective such
Registration Statement in the same manner as otherwise contemplated in this Agreement for Registration Statements hereunder, in each case until such time as: (i) all Registrable Securities held by such Investor have been
registered and sold pursuant to an effective Registration Statement in a manner acceptable to such Investor, or (ii) the Registrable Securities may be immediately sold without registration and without restriction (including without
limitation as to manner of sale volume by each holder thereof) as to the number of Registrable Securities to be sold, pursuant to Rule 144 or otherwise (it being understood that the special demand right under this sentence may be exercised by
an Investor multiple times and with respect to limited amounts of Registrable Securities in order to permit the resale thereof by such Investor as contemplated above). 
 2.2 Effectiveness of the Registration Statement. 
 (a) The Company will use
its best efforts to cause each Registration Statement contemplated by Section 2.1 to be declared effective by the SEC as soon as practicable after filing, and in any event no later than the 120th day after the Required Filing Date (the
“Required Effective Date”). If the SEC takes the position that under Rule 415 of the Securities Act, the amount of Registrable Securities needs to be reduced to clear the SEC review, the Investors shall agree to reduce their
Registrable Securities to be registered pro rata to meet the SEC requirement with the understanding the Company shall promptly file another Registration Statement to register the Registrable Securities not registered at a time when such Registration
Statement is allowed. 
 (b) The Company’s best efforts will include, but not be limited to, promptly responding to all
comments received from the staff of the SEC. If the Company receives notification from the SEC that a Registration Statement will receive no action or review from the SEC, then the Company will cause such Registration Statement to become effective
as soon as practicable after such SEC notification. 
 (c) Once a Registration Statement is declared effective by the SEC, the
Company will cause such Registration Statement to remain effective throughout the applicable Registration Period, in each case except as permitted under Section 3.1. 
 2.3 Payments by the Company. If (i) at any time after effectiveness of a Registration Statement, sales cannot be made thereunder during the applicable Registration Period for any reason
(including any suspension of the use of a Registration Statement under Section 3.6 hereof) for a period of more than 10 consecutive business days, or 30 days in the aggregate, during any 12-month period or (ii) the Common Stock is not
listed on a National Securities Exchange or included for quotation on the OTC Bulletin Board for more than an aggregate of 10 business days in any 12-month period, then the Company will thereafter make a payment (by wire transfer or check) to each
Investor as partial compensation for such delay. The amount of the payment made to each Investor will be equal to 0.5% of the Outstanding Principal Amount (as hereinafter

  

 4 

 
defined) for the each month that sales cannot be made under the effective Registration Statement or the Common Stock is not listed on a National Securities Exchange or included for quotation on
the OTC Bulletin Board continuing through the date that sales can be made under the effective Registration Statement or the Common Stock is listed on a National Securities Exchange or included for quotation on the OTC Bulletin Board. The term
“Outstanding Principal Amount” for purposes of computing the amount of payment to be made to an Investor under Section 2.3 and Section 2.4 shall mean the sum of (x) the number of such Commitment Shares held by such
Investor multiplied by the closing market price of the Common Stock on the principal National Securities Exchange on which the Common Stock is traded as of, or if the Common Stock is not so traded, the last trading price of the Common Stock on the
OTC Bulletin Board on or prior to, the date on which such Commitment Shares were issued, and (y) for each issuance of Payment Shares, the number of such Payment Shares held by such Investor multiplied by the closing market price of the Common
Stock on the principal National Securities Exchange on which the Common Stock is traded, or the OTC Bulletin Board, as of the date on which such Payment Shares were issued. Such payments will be prorated on a daily basis for partial months and will
be paid to each Investor by wire transfer or check within five business days following the end of each month. 
 2.4 Effect
of Late Filing or Effectiveness. If (a) the Company fails to file any Registration Statement by the time required by Section 2.1 (a “Filing Failure”); (b) any Registration Statement required pursuant to
Section 2.1 above has not been declared effective by the Required Effective Date for any reason, including, without limitation, by reason of the inability of the Company to utilize a particular registration statement form that would provide for
a shorter time to effectiveness, the failure by the Company to file its reports required under the Exchange Act or the Company’s failure to fulfill its obligations under Section 2.1(a) and Section 2.2(b) (an “Effectiveness
Failure”), then the Company shall pay to each Investor, for each day of such Filing Failure or Effectiveness Failure, an amount equal to the product of (i) such Investor’s Outstanding Principal Amount and (ii) the quotient
obtained by dividing 6% by 360 (the “Late Payments”). The Late Payments will be paid to the Investors by wire transfer or check within five business days after the earlier of (i) the end of each month following the Required
Filing Date or Required Effective Date or (ii) the effective date of the applicable Registration Statement. Nothing herein limits any Investor’s right to pursue actual damages for the Company’s failure to file a Registration Statement
on or prior to the Required Filing Date or to have it declared effective by the SEC on or prior to the Required Effective Date in accordance with the terms of this Agreement. 
 2.5 Piggyback Registrations. 
 (a) If, at any time prior to the expiration of a Registration Period, a Registration Statement is not effective with respect to all of the Registrable Securities and the Company decides to register any of
its securities for its own account or for the account of others, then the Company will promptly give the Investors written notice thereof and will use its best efforts to include in such registration all or any part of the Registrable Securities
requested by such Investors to be included therein (excluding any Registrable Securities previously included in a Registration Statement). This requirement does not apply to Company registrations on Form S-4 or S-8 or their equivalents relating to
equity securities to be issued solely in connection with

  

 5 

 
an acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans. Each Investor must give its request for registration under
this paragraph to the Company in writing within 15 days after receipt from the Company of notice of such pending registration. If the registration for which the Company gives notice is a public offering involving an underwriting, the Company will so
advise the Investors as part of the above-described written notice. In that event, if the managing underwriter(s) of the public offering impose a limitation (which may be a complete exclusion) on the number of shares of Common Stock that may be
included in a Registration Statement because, in such underwriter(s)’ judgment, such limitation would be necessary to effect an orderly public distribution or reduce the number of securities which could be sold by the Company, then the Company
will be obligated to include only such limited portion, if any, of the Registrable Securities with respect to which such Investors have requested inclusion hereunder. Any exclusion of Registrable Securities will be made pro rata among all holders of
the Company’s securities seeking to include shares of Common Stock in proportion to the number of shares of Common Stock sought to be included by those holders. However, the Company will not exclude any Registrable Securities unless the Company
has first excluded all outstanding securities the holders of which are not entitled by right to inclusion of securities in such Registration Statement or are not entitled pro rata inclusion with the Registrable Securities. If any Investor or other
person does not agree to the terms of such underwriting or otherwise fails to comply with the terms of this Agreement, such Investor or other person shall be excluded therefrom upon written notice from the Company or underwriter. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 (b) No
right to registration of Registrable Securities under this Section 2.5 limits in any way the registration required under Section 2.1 above. The obligations of the Company under this Section 2.5 expire upon the earliest of (i) the
effectiveness of a Registration Statement filed pursuant to Section 2.1 above with respect to the Registrable Securities or the respective portion thereof, (ii) after the Company has afforded the opportunity for the Investors to exercise
registration rights under this Section 2.5 for two registrations (provided, however, that any Investor that has had any Registrable Securities excluded from any Registration Statement in accordance with this Section 2.5 may include
in any additional Registration Statement filed by the Company the Registrable Securities so excluded), or (iii) expiration of the Registration Period. 
 (c) The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.5 prior to the effectiveness of such registration whether or not any Investor has
elected to include securities in such registration. The expenses of such withdrawn registration shall be borne by the Company. 
 2.6 Eligibility to use Form S-1 or S-3. The Company represents and warrants that it meets the requirements for the use of Form S-1 or S-3 for registration of the resale by the Investors of the Registrable Securities. The
Company will file all reports required to be filed by the Company with the SEC in a timely manner so as to preserve its eligibility for the use of Form S-1 or S-3. 
  

 6 

 ARTICLE III 
 ADDITIONAL OBLIGATIONS OF THE COMPANY 
 3.1
Continued Effectiveness of Registration Statements. The Company will keep each Registration Statement covering the Registrable Securities effective under Rule 415 at all times during the applicable Registration Period. In the event that
the number of shares available under a Registration Statement filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities, the Company will (if permitted) amend such Registration Statement or file a new Registration
Statement (on the short form available therefor, if applicable), or both, so as to cover all of the Registrable Securities. The Company will file such amendment or new Registration Statement as soon as practicable, but in no event later than 20
business days after the necessity therefor arises (based upon the market price of the Common Stock and other relevant factors on which the Company reasonably elects to rely). The Company will use its best efforts to cause such amendment or new
Registration Statement to become effective as soon as is practicable after the filing thereof, but in no event later than 90 days after the date on which the Company reasonably first determines (or reasonably should have determined) the need
therefor. 
 3.2 Accuracy of Registration Statement. Any Registration Statement (including any amendments or supplements
thereto and prospectuses contained therein) filed by the Company covering Registrable Securities will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the
statements therein, in light of the circumstances in which they were made, not misleading. The Company will promptly prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement
and the prospectus used in connection with such Registration Statement as may be necessary to permit sales pursuant to such Registration Statement at all times during the Registration Period, and, during such period, will comply with the provisions
of the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by such Registration Statement until the termination of such Registration Period, or if earlier, until such time as all of such Registrable
Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. 
 3.3 Furnishing Documentation. The Company will furnish to each Investor whose Registrable Securities are included in a Registration Statement, and to its legal counsel, (a) promptly after each
document is prepared and publicly distributed, filed with the SEC or received by the Company, one copy of any Registration Statement filed pursuant to this Agreement and any amendments thereto, each preliminary prospectus and final prospectus and
each amendment or supplement thereto; and, in the case of a Registration Statement filed under Section 2.1 above, each letter written by or on behalf of the Company to the SEC and each item of correspondence from, or order issued by, the SEC or
the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any item thereof which contains information for which the Company has sought confidential treatment); and (b) a number of copies of a
prospectus, including a preliminary prospectus (if any), and all amendments and supplements thereto, and such other documents as the Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by the
Investor. The Company will promptly notify in writing each Investor whose Registrable Securities are included in any Registration Statement of the effectiveness of such Registration Statement and any post-effective amendment. 
  

 7 

 3.4 Additional Obligations. The Company will use its best efforts to
(a) register and qualify the Registrable Securities covered by a Registration Statement under such other securities or blue sky laws of such jurisdictions as each Investor who holds (or has the right to hold) Registrable Securities being
offered reasonably requests, (b) prepare and file in those jurisdictions any amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain their effectiveness during
the Registration Period, (c) take any other actions necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (d) take any other actions reasonably necessary or advisable to
qualify the Registrable Securities for sale in such jurisdictions. Notwithstanding the foregoing, the Company is not required, in connection such obligations, to (i) qualify to do business in any jurisdiction where it would not otherwise be
required to qualify but for this Section 3.4, (ii) subject itself to general taxation in any such jurisdiction, (iii) file a general consent to service of process in any such jurisdiction, (iv) provide any undertakings that cause
material expense or burden to the Company, or (v) make any change in its charter or bylaws, which in each case the Board of Directors of the Company determines to be contrary to the best interests of the Company and its stockholders.

 3.5 Underwritten Offerings. If the Investors who hold a majority in interest of the Registrable Securities being
offered in an offering pursuant to a Registration Statement or any amendment or supplement thereto under this Agreement select underwriters reasonably acceptable to the Company for such offering, the Company will enter into and perform its
obligations under an underwriting agreement in usual and customary form including, without limitation, customary indemnification and contribution obligations, with the managing underwriter of such offering, but the Company will not be obligated to
pay any fees or expenses of such underwriters related to the offering. 
 3.6 Suspension of Registration. 
 (a) The Company will notify (by telephone and also by facsimile and reputable overnight courier) each Investor who holds Registrable
Securities being sold pursuant to a Registration Statement of the happening of any event of which the Company has knowledge as a result of which the prospectus included in a Registration Statement as then in effect includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company will make such notification as
promptly as practicable after the Company becomes aware of the event (but in no event will the Company disclose to any Investor any of the facts or circumstances regarding the event), will promptly (but in no event more than ten business days)
prepare a supplement or amendment to such Registration Statement to correct such untrue statement or omission, and will deliver a number of copies of such supplement or amendment to each Investor as such Investor may reasonably request. The Company
will use its best efforts to keep the length of any such suspension to as short a period as is practicable given the then existing circumstances and may so defer or suspend the use of a Registration Statement no more than two times in any 18-month
period, and provided, further,

  

 8 

 
that, after deferring or suspending the use of a Registration Statement, the Company may not again defer or suspend the use of such Registration Statement until a period of thirty days has
elapsed after resumption of the use of such Registration Statement. Notwithstanding anything to the contrary contained herein or in the Exchange Agreement, if the use of a Registration Statement is suspended by the Company, the Company will promptly
give notice of the suspension to all Investors whose securities are covered by such Registration Statement, and will promptly notify each such Investor as soon as the use of such Registration Statement may be resumed. Notwithstanding anything to the
contrary contained herein or in the Credit Agreement, the Company will cause the Transfer Agent to deliver unlegended shares of Common Stock to a transferee of an Investor in connection with any sale of Registrable Securities with respect to which
such Investor has entered into a contract for sale prior to receipt of notice of such suspension and for which such Investor has not yet settled unless, in the opinion of Company’s legal counsel, such delivery without legends would be in
violation of applicable securities laws and/or otherwise subject the Company to liability. 
 (b) Notwithstanding anything to
the contrary herein (but subject to the last sentence of this Section 3.6(b)), at any time after the Effective Date of the applicable Registration Statement, the Company may delay the disclosure of material, non-public information concerning
the Company or any of its Subsidiaries the disclosure of which at the time is not, in the good faith opinion of the Board of Directors of the Company, in the best interest of the Company and, in the opinion of counsel to the Company, otherwise
required (a “Grace Period”); provided, that the Company shall promptly (i) notify the Investors in writing of the existence of material, non-public information giving rise to a Grace Period (provided that in each
notice the Company will not disclose the content of such material, non-public information to the Investors) and the date on which the Grace Period will begin, and (ii) notify the Investors in writing of the date on which the Grace Period ends;
and, provided further, that no Grace Period shall exceed ten (10) consecutive days and during any three hundred sixty five (365) day period such Grace Periods shall not exceed an aggregate of thirty (30) days and the
first day of any Grace Period must be at least five (5) Trading Days after the last day of any prior Grace Period; provided, that no Grace Period may exist during the first sixty (60) Business Days after the Effective Date of the
applicable Registration Statement. For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred to in clause (i) and shall end on and include the
later of the date the Investors receive the notice referred to in clause (ii) and the date referred to in such notice. The provisions of Section 3.6(a) hereof shall not be applicable during any Grace Period. Upon expiration of the Grace
Period, the Company shall again be bound by Section 3.6(a) with respect to the information giving rise thereto unless such material, nonpublic information is no longer applicable. 
 (c) Subject to the Company’s rights under Section 3.1, the Company will use its best efforts to prevent the issuance of any stop
order or other suspension of effectiveness of a Registration Statement and, if such an order is issued, will use its best efforts to obtain the withdrawal of such order at the earliest possible time and will promptly notify each Investor that holds
Registrable Securities being sold (or, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof. 
  

 9 

 3.7 Review by the Investors. The Company will permit each Investor’s legal
counsel to review each Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof) a reasonable period of time prior to their filing with the SEC, and will not file any
document in a form to which such counsel reasonably objects unless such counsel fails to notify the Company of his or her objection within 3 business days after receipt of the proposed Registration Statement, and unless otherwise required by law in
the opinion of the Company’s counsel. The sections of any such Registration Statement including information with respect to the Investors, the Investors’ beneficial ownership of securities of the Company or the Investors’ intended
method of disposition of Registrable Securities must conform to the information provided to the Company by each of the Investors. 
 3.8 Information. The Company will make generally available to its security holders as soon as practicable, but not later than 90 days after the close of the period covered thereby, an earnings statement (in a form complying with the
provisions of Rule 158 under the Securities Act) covering a 12-month period beginning not later than the first day of the Company’s fiscal quarter next following the effective date of a Registration Statement. 
 3.9 Comfort Letter; Legal Opinion. If the Investors request an underwritten offering in accordance with Section 3.5 above, then,
at the request of the underwriters for the offering, on the date that Registrable Securities are delivered to the underwriters for sale in connection with a Registration Statement, the Company will furnish to the Investors and the underwriters
(i) a letter, dated such date, from the Company’s independent certified public accountants, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters; and (ii) an opinion, dated such date, from counsel representing the Company for purposes of such Registration Statement, in form and substance as is customarily given in an underwritten public offering, addressed
to the underwriters and Investors. 
 3.10 Due Diligence; Confidentiality. 
 (a) The Company will make available for inspection by any Investor whose Registrable Securities are being sold pursuant to a Registration
Statement, any underwriter participating in any disposition pursuant to such Registration Statement, and any attorney or accountant retained by any such Investor or underwriter (collectively, the “Inspectors”), all pertinent
financial and other records, pertinent corporate documents and properties of the Company (collectively, the “Records”), as each Inspector reasonably deems necessary to enable the Inspector to exercise its due diligence
responsibility in connection with or related to the contemplated offering. The Company will cause its officers, directors and employees to supply all information that any Inspector may reasonably request for purposes of performing such due
diligence. 
 (b) Each Inspector will hold in confidence, and will not make any disclosure (except to an Investor) of, any
Records or other information that the Company determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (i) the disclosure of such Records is necessary to avoid or correct a misstatement or
omission in any Registration Statement, (ii) the release of such Records is ordered pursuant to a subpoena or

  

 10 

 
other order from a court or government body of competent jurisdiction, (iii) the information in such Records has been made generally available to the public other than by disclosure in
violation of this or any other agreement (to the knowledge of the relevant Inspector), (iv) the Records or other information was developed independently by an Inspector without breach of this Agreement, (v) the information was known to the
Inspector before receipt of such information from the Company, or (vi) the information was disclosed to the Inspector by a third party not under an obligation of confidentiality. The Company is not required to disclose any confidential
information in the Records to any Inspector unless and until such Inspector has entered into a confidentiality agreement (in form and substance satisfactory to the Company) with the Company with respect thereto, substantially in the form of this
Section 3.10. Each Investor will, upon learning that disclosure of Records containing confidential information is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Company
and allow the Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein will be deemed to limit the Investor’s ability
to sell Registrable Securities in a manner that is otherwise consistent with applicable laws and regulations. 
 (c) The Company
will hold in confidence, and will not make any disclosure of, information concerning an Investor provided to the Company under this Agreement unless (i) disclosure of such information is necessary to comply with federal or state securities
laws, or any exchange listing or similar rules and regulations, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is
ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any
other agreement or (v) such Investor consents to the form and content of any such disclosure. If the Company learns that disclosure of such information concerning an Investor is sought in or by a court or governmental body of competent
jurisdiction or through other means, the Company will give prompt notice to such Investor prior to making such disclosure and allow such Investor, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective
order for, such information. 
 3.11 Listing. The Company will (i) cause all of the Common Shares covered by each
Registration Statement to be listed on each National Securities Exchange on the Common Stock is then listed, if any, if the listing of such Common Shares is then permitted under the rules of such exchange, or (ii) to the extent the Common Stock
is not then listed on a National Securities Exchange, secure the quotation of all of the Common Shares covered by each Registration Statement on the OTC Bulletin Board and, without limiting the generality of the foregoing, arrange for at least two
market makers, meeting the applicable FINRA requirements, to display two-sided markets for the Common Stock. 
 3.12 Transfer
Agent; Registrar. The Company will provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of each Registration Statement. 
  

 11 

 3.13 Share Certificates. The Company will cooperate with the Investors who hold
Registrable Securities being sold and with the managing underwriter(s), if any, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to a
Registration Statement and will enable such certificates to be in such denominations or amounts as the case may be, and registered in such names as the Investors or the managing underwriter(s), if any, may reasonably request. 
 3.14 Plan of Distribution. Subject to Section 3.17 hereof, at the request of an Investor holding an interest of the Registrable
Securities registered pursuant to a Registration Statement, the Company will promptly prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement, and the prospectus used in
connection with a Registration Statement, as may be necessary in order to change the plan of distribution set forth in such Registration Statement. 
 3.15 Securities Laws Compliance. The Company will comply with all applicable laws related to any Registration Statement relating to the sale of Registrable Securities and to offering and sale of
securities and with all applicable rules and regulations of governmental authorities in connection therewith (including, without limitation, the Securities Act, the Exchange Act and the rules and regulations promulgated by the SEC). 
 3.16 Further Assurances. The Company will take all other reasonable actions as any Investor or the underwriters, if any, may
reasonably request to expedite and facilitate disposition by such Investor of the Registrable Securities pursuant to a Registration Statement. 
 3.17 No Additional Selling Securityholders. The Company will not, and will not agree to, allow the holders of any securities of the Company to include any of their securities in any Registration
Statement under Section 2.1 hereof, or any amendment or supplement thereto under Section 3.2 hereof, without the consent of all of the holders of the Registrable Securities. 
 ARTICLE IV 
 OBLIGATIONS OF THE INVESTORS

 4.1 Investor Information. As a condition to the obligations of the Company to complete any registration pursuant
to this Agreement with respect to the Registrable Securities of each Investor, such Investor will furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the
Registrable Securities held by it as is reasonably required by the Company to effect the registration of the Registrable Securities. At least 10 business days prior to the first anticipated filing date of a Registration Statement for any
registration under this Agreement, the Company will notify each Investor of the information the Company requires from that Investor if the Investor elects to have any of its Registrable Securities included in such Registration Statement. If, within
three business days prior to the filing date, the Company has not received the requested information from an Investor, then the Company may file such Registration Statement without including Registrable Securities of that Investor. Any and all
information provided by the Investor pursuant to this Section 4.1 shall be true, accurate, correct and complete in all material respects. 
  

 12 

 4.2 Further Assurances. Each Investor will cooperate with the Company, as reasonably
requested by the Company, in connection with the preparation and filing of any Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor’s election to exclude all of such Investor’s
Registrable Securities from such Registration Statement. 
 4.3 Suspension of Sales. Upon receipt of any notice from the
Company of the happening of any event of the kind described in Section 3.6, each Investor will immediately discontinue disposition of Registrable Securities pursuant to the applicable Registration Statement covering such Registrable Securities
until (i) it receives copies of a supplemented or amended prospectus contemplated by Section 3.6 or (ii) the Company advises the Investor that a suspension of sales under Section 3.6 has terminated. If so directed by the Company,
each Investor will deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in the Investor’s possession (other than a limited number of file copies) of the
prospectus covering such Registrable Securities that is current at the time of receipt of such notice. 
 4.4 Underwritten
Offerings. 
 (a) If Investors holding a majority in interest of the Registrable Securities being registered (with the
approval of a majority in interest of the Investors) elect to engage the services of an underwriter, each Investor will enter into and perform such Investor’s obligations under an underwriting agreement, in usual and customary form, including,
without limitation, customary indemnification and contribution obligations, with the managing underwriter of such offering, and will take such other actions as are reasonably required in order to expedite or facilitate the disposition of the
Registrable Securities, unless such Investor has notified the Company in writing of such Investor’s election to exclude all of its Registrable Securities from such Registration Statement. 
 (b) Without limiting any Investor’s rights under Section 2.1 hereof, no Investor may participate in any underwritten distribution
hereunder unless such Investor (i) agrees to sell such Investor’s Registrable Securities on the basis provided in any underwriting arrangements approved by the Investors entitled hereunder to approve such arrangements, (ii) completes
and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements, and (iii) agrees to pay its pro rata share of all underwriting
discounts and commissions and other fees and expenses of investment bankers and any manager or managers of such underwriting, and legal expenses of the underwriter, applicable with respect to its Registrable Securities, in each case to the extent
not payable by the Company under the terms of this Agreement. 
 ARTICLE V 
 EXPENSES OF REGISTRATION 
 The Company will bear all reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to

  

 13 

 
Articles II and III of this Agreement, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, the fees and disbursements of counsel for
the Company, and the reasonable fees and disbursements of each Investor’s legal counsel to review each Registration Statement and all amendments and supplements thereto pursuant to Section 3.7 hereof. 
 ARTICLE VI 
 INDEMNIFICATION 
 In the event that any Registrable Securities are included in a Registration Statement under
this Agreement: 
 6.1 To the extent permitted by law, the Company will indemnify and hold harmless each Investor that holds
such Registrable Securities, any underwriter (as defined in the Securities Act) for the Investors, any directors, officers or advisors of such Investor or such underwriter and any person who controls such Investor or such underwriter within the
meaning of the Securities Act or the Exchange Act (each, an “Indemnified Person”) against any losses, claims, damages, expenses or liabilities (joint or several) (collectively, and together with actions, proceedings or inquiries by
any regulatory or self-regulatory organization, whether commenced or threatened in respect thereof, “Claims”) to which any of them become subject under the Securities Act, the Exchange Act or otherwise, insofar as such Claims arise
out of or are based upon any of the following statements, omissions or violations in a Registration Statement filed pursuant to this Agreement, any post-effective amendment thereof or any prospectus included therein: (a) any untrue statement or
alleged untrue statement of a material fact contained in such Registration Statement or any post-effective amendment thereof or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, (b) any untrue statement or alleged untrue statement of a material fact contained in the prospectus (as it may be amended or supplemented) or the omission or alleged omission to state therein any material fact
necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading, or (c) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any
other law, including without limitation any state securities law or any rule or regulation thereunder (the matters in the foregoing clauses (a) through (c) being, collectively, “Violations”). The Company will
reimburse the Investors and each such underwriter or controlling person and each such other Indemnified Person, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in
connection with investigating or defending any Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6.1 (i) does not apply to Claims arising out of or based upon a
Violation that occurs in reliance upon and in conformity with information furnished in writing to the Company by an Indemnified Person expressly for use in connection with the preparation of a Registration Statement or any such amendment thereof or
supplement thereto, if such prospectus was timely made available by the Company pursuant to Section 3.3 hereof; and (ii) does not apply to amounts paid in settlement of any Claim if such settlement is made without the prior written consent
of the Company, which consent will not be unreasonably withheld. This indemnity obligation will remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Persons and will survive the transfer of the
Registrable Securities by the Investors under Article IX of this Agreement. 
  

 14 

 6.2 In connection with any Registration Statement in which an Investor is participating,
each such Investor will indemnify and hold harmless, to the same extent and in the same manner set forth in Section 6.1 above, the Company, each of its directors, each of its officers who signs such Registration Statement, each person, if any,
who controls the Company within the meaning of the Securities Act or the Exchange Act, and any other shareholder selling securities pursuant to such Registration Statement and any of its directors and officers and any person who controls such
shareholder within the meaning of the Securities Act or the Exchange Act (each an “Indemnified Person”) against any Claim to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, insofar as
such Claim arises out of or is based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished to the Company by such Investor expressly
for use in connection with such Registration Statement. Subject to the restrictions set forth in Section 6.3, such Investor will promptly reimburse the Company and each such other Indemnified Person, any legal or other expenses (promptly as
such expenses are incurred and due and payable) reasonably incurred by them in connection with investigating or defending any such Claim. However, the indemnity agreement contained in this Section 6.2 does not apply to amounts paid in
settlement of any Claim if such settlement is effected without the prior written consent of such Investor, which consent will not be unreasonably withheld, and no Investor will be liable under this Agreement (including this Section 6.2 and
Article VII) for the amount of any Claim that exceeds the net proceeds actually received by such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. This indemnity will remain in full force and effect
regardless of any investigation made by or on behalf of an Indemnified Party and will survive the transfer of the Registrable Securities by the Investors under Article IX of this Agreement. 
 6.3 Promptly after receipt by an Indemnified Person under this Article VI of notice of the commencement of any action (including any
governmental action), such Indemnified Person will, if a Claim in respect thereof is to be made against any indemnifying party under this Article VI, deliver to the indemnifying party a written notice of the commencement thereof. The indemnifying
party may participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly given notice, assume control of the defense thereof with counsel mutually satisfactory to the indemnifying parties
and the Indemnified Person. In that case, the indemnifying party will diligently pursue such defense. If, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person and the
indemnifying party would be inappropriate due to actual or potential conflicts of interest between the Indemnified Person and any other party represented by such counsel in such proceeding or the actual or potential defendants in, or targets of, any
such action including the Indemnified Person, and such Indemnified Person reasonably determines that there may be legal defenses available to such Indemnified Person that are different from or in addition to those available to the indemnifying
party, then the Indemnified Person is entitled to assume such defense and may retain its own counsel, with the fees and expenses to be paid by the indemnifying party (subject to the restrictions on settlement under Section 6.1 or
Section 6.2, as applicable). The failure to deliver written notice to the

  

 15 

 
indemnifying party within a reasonable time of the commencement of any such action does not relieve an indemnifying party of any liability to an Indemnified Person under this Article VI,
except to the extent that the indemnifying party is prejudiced in its ability to defend such action. The indemnification required by this Article VI will be made by periodic payments of the amount thereof during the course of the investigation
or defense, as such expense, loss, damage or liability is incurred and is due and payable. Each Indemnified Person shall furnish such information regarding itself or the claim in question as an Indemnifying Person may reasonably request in writing
and shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 
 ARTICLE
VII 
 CONTRIBUTION 
 To the extent that any indemnification provided for herein is prohibited or limited by law, the indemnifying party will make the maximum contribution with respect to any amounts for which it would
otherwise be liable under Article VI to the fullest extent permitted by law. However, (a) no contribution will be made under circumstances where the maker would not have been liable for indemnification under the fault standards set forth
in Article VI, (b) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any seller of Registrable Securities who
was not guilty of such fraudulent misrepresentation, and (c) contribution (together with any indemnification or other obligations under this Agreement) by any seller of Registrable Securities will be limited in amount to the net amount of
proceeds received by such seller from the sale of such Registrable Securities. 
 ARTICLE VIII 
 EXCHANGE ACT REPORTING 
 In order to make available to the Investors the benefits of Rule 144 or any similar rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the
public without registration, the Company will: 
 (a) File with the SEC in a timely manner, and make and keep available, all
reports and other documents required of the Company under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements and the filing and availability of such reports and other documents is required for the
applicable provisions of Rule 144; and 
 (b) Furnish to each Investor who so requests, so long as such Investor holds 2010
Convertible senior Notes or Registrable Securities, promptly upon the Investor’s request, (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange
Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents filed by the Company with the SEC and (iii) such other information as may be reasonably requested to permit the Investors to
sell such securities pursuant to Rule 144 without registration. 
  

 16 

 ARTICLE IX 
 ASSIGNMENT OF REGISTRATION RIGHTS 
 The rights of the
Investors hereunder, including the right to have the Company register Registrable Securities pursuant to this Agreement, will be automatically assigned by the Investors to transferees or assignees of all or any portion of the Investors rights under
the Credit Agreement, or interests in the Registrable Securities, but only if (a) the Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable
time after such assignment, (b) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such
registration rights are being transferred or assigned, (c) after such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws,
(d) at or before the time the Company received the written notice contemplated by clause (b) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein,
(e) such transfer is made in accordance with the applicable requirements of the Credit Agreement, and (f) the transferee is an “accredited investor” as that term is defined in Rule 501 under the Exchange Act. Any transferee
or assignee of an Investor under this Article IX shall be deemed an “Investor” for all purposes of this Agreement, and shall be entitled to all rights of, and subject to all obligations (including indemnification obligations) of, an
Investor hereunder; provided, however, that such a transferee will not be eligible to be named in a Registrations Statement or an amendment thereto until such transferee has completed a Questionnaire of Selling Securityholders in the form of
Exhibit A and delivered it to the Company. 
 ARTICLE X 
 AMENDMENT OF REGISTRATION RIGHTS 
 This Agreement may
be amended and the obligations hereunder may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and each Investor (but not including any Investor who is
not affected by such amendment or waiver). Any amendment or waiver effected in accordance with this Article X is binding upon each Investor (and each future holder of all such Registrable Securities) and the Company. Notwithstanding the
foregoing, no amendment or waiver will retroactively affect any Investor without its consent, or will prospectively adversely affect any Investor who no longer owns any 2010 Convertible Senior Notes or Registrable Securities without its consent.
Neither Article VI nor Article VII hereof may be amended or waived in a manner adverse to an Investor without its consent. 
 ARTICLE XI 
 MISCELLANEOUS 
 11.1 Conflicting Instructions. A person or entity is deemed to be a holder of Registrable Securities whenever such person or entity owns of record such Registrable Securities. If the Company
receives conflicting instructions, notices or elections from two or more persons or entities with respect to the same Registrable Securities, the Company will act upon the basis of instructions, notice or election received from the registered owner
of such Registrable Securities. 
  

 17 

 11.2 Notices. Any notices required or permitted to be given under the terms of
this Agreement will be given and deemed received as set forth in Section 9.9 of the Credit Agreement. 
 11.3
Waiver. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, does not operate as a waiver thereof. 
 11.4 Governing Law; Dispute Resolution. This Agreement will be governed by and interpreted in accordance with the laws of the
State of Minnesota without regard to the principles of conflict of laws. All disputes, differences, controversies and claims arising out of or relating to this Agreement shall be resolved in accordance with Section 9.13 of the Exchange
Agreement. 
 11.5 Severability. If any provision of this Agreement is invalid or unenforceable under any applicable
statute or rule of law, then such provision will be deemed modified in order to conform to such statute or rule of law. Any provision hereof that may prove invalid or unenforceable under any law will not affect the validity or enforceability of any
other provision hereof. 
 11.6 Entire Agreement. This Agreement and the Credit Agreement (including all schedules and
exhibits thereto) (the “Transaction Documents”) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other
than those set forth or referred to herein or therein. This Agreement supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof. 
 11.7 Successors and Assigns. Subject to the requirements of Article IX hereof, this Agreement inures to the benefit of
and is binding upon the successors and assigns of each of the parties hereto. Notwithstanding anything to the contrary herein, including, without limitation, Article IX, the rights of an Investor hereunder are assignable to and exercisable by a
bona fide pledgee of the Registrable Securities in connection with an Investor’s margin or brokerage accounts. 
 11.8
Use of Pronouns. All pronouns refer to the masculine, feminine or neuter, singular or plural, as the context may require. 
 11.9 Headings. The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not affect its interpretation. 
 11.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which is deemed an original but all of
which constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission, and facsimile signatures are binding on the parties hereto. 
  

 18 

 11.11 Further Assurances. Each party will do and perform, or cause to be done
and performed, all such further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as another party may reasonably request in order to carry out the intent and accomplish the purposes of this
Agreement and the consummation of the transactions contemplated hereby. 
 11.12 Consents. All consents and other
determinations to be made by the Investors pursuant to this Agreement will be made by the Investors holding a majority in interest of the then-outstanding Registrable Securities, determined as if all 2010 Convertible Senior Notes then outstanding
had been converted into or exercised for Registrable Securities. 
 11.13 No Strict Construction. The language used in
this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 11.14 No Third-Party Beneficiaries. Other than as specifically provided herein, this Agreement is intended to inure to the benefit of the parties hereto only, and no other party shall have any
rights, express or implied, by reason of this Agreement. 
 11.15 Saturdays, Sundays, Holidays, Etc. If the last or
appointed day for the taking of any action required or permitted hereby shall be a Saturday, Sunday, a nationally recognized holiday, or a state holiday in the State of Minnesota, then such action may be taken on the next succeeding business day.

 11.16 Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any of the
Transaction Documents are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. Nothing
contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Document. Each Investor shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company
has elected to provide all Investors with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by the Investors. 
 [signature pages follow] 
  

 19 

 IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Agreement to
be duly executed as of the date first above written. 
  

			
	COMPANY:
	
	FLOTEK INDUSTRIES, INC.
		
	 By:
	 	 /s/ John Chisholm

		 	 Name: John Chisholm

		 	 Title: President

 [Signatures continued on next page] 
 [Signature Page to Registration
Rights Agreement - Credit Agreement] 

			
	INVESTORS:
	 WHITEBOX HEDGED HIGH YIELD
 PARTNERS, LP

		
	 By:
	 	Whitebox Hedged High Yield Advisors, LLC
	Its:	 	General Partner
		 	
	By:	 	Whitebox Advisors LLC
	Its:	 	Managing Member
		 	
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer
	
	IAM MINI-FUND 14 LIMITED
		
	By:	 	Whitebox Advisors LLC
	Its:	 	Investment Manager
		 	
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer

 [Signature
Page to Registration Rights Agreement - Credit Agreement] 

  

			
	PANDORA SELECT PARTNERS, LP
		
	By:	 	Pandora Select Advisors, LLC
	Its:	 	General Partner
		
	By:	 	Whitebox Advisors LLC
	Its:	 	Managing Member
		
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer
	
	 WHITEBOX SPECIAL OPPORTUNITIES FUND, LP – SERIES B

		
	By:	 	Whitebox Special Opportunities Advisors, LLC
	Its:	 	General Partner
		
	By:	 	Whitebox Advisors LLC
	Its:	 	Managing Member
		
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer
	
	WHITEBOX COMBINED PARTNERS, LP
		
	By:	 	Whitebox Combined Advisors, LLC
	Its:	 	General Partner
		
	By:	 	Whitebox Advisors LLC
	Its:	 	Managing Member
		
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer

 [Signature
Page to Registration Rights Agreement] 

			
	 WHITEBOX CONVERTIBLE ARBITRAGE PARTNERS, LP

		
	By:	 	Whitebox Convertible Arbitrage Advisors, LLC
	Its:	 	General Partner
		
	By:	 	Whitebox Advisors LLC
	Its:	 	Managing Member
		
	By:	 	 /s/ Mark Strefling

	Name:	 	Mark Strefling
	Title:	 	Chief Legal Officer

 ADDRESS: 
 c/o Whitebox Advisors, LLC 
 3033 Excelsior Blvd., Suite 300 
 Minneapolis, MN 55416 
 Attention: Jake Mercer 
 Facsimile: 612-253-6100 
 (any notice hereunder to this Investor shall include a copy to): 
 Faegre & Benson LLP 
 2200 Wells Fargo Center 
 90 South Seventh Street 
 Minneapolis, Minnesota 55402 
 Attn: Michael K. Coddington 
 Facsimile: 612-766-1600 
 [Signature Page to Registration Rights Agreement] 

			
	ECF VALUE FUND, L.P.
		
	By:	 	Gates Capital Partners, L.P.
	Its:	 	General Partner
		
	By:	 	Gates Capital Management, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Jeffrey L. Gates

	Name:	 	Jeffrey L. Gates
	Title:	 	President
	
	ECF VALUE FUND II, L.P.
		
	By:	 	Gates Capital Partners, L.P.
	Its:	 	General Partner
		
	By:	 	Gates Capital Management, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Jeffrey L. Gates

	Name:	 	Jeffrey L. Gates
	Title:	 	President
	
	ECF VALUE FUND INTERNATIONAL LTD.
		
	By:	 	Gates Capital Management, Inc.
	Its:	 	Investment Advisor
		
	By:	 	 /s/ Jeffrey L. Gates

	Name:	 	Jeffrey L. Gates
	Title:	 	President

 [Signature Page to
Registration Rights Agreement] 

 EXHIBIT A 
 FLOTEK INDUSTRIES, INC. 
 (the “Company”) 
 QUESTIONNAIRE TO THE SELLING SECURITYHOLDERS 
 This Questionnaire is to be completed, signed and faxed or emailed to                     at
                    or                     , by
the person or entity indicated on the cover of this Questionnaire (the “Selling Securityholder”) whose securities of the Company are being registered pursuant to a Registration Statement on Form S-3. Retain a duplicate copy for your files.
If you do not return the Questionnaire by the foregoing deadline, your shares may not be included in the Registration Statement. 
 If you are uncertain about any of the following questions as they apply to your situation, please supply all relevant facts. Include separate sheets with details if necessary. If you have any questions, please call the Company’s
counsel, W. Mark Young, Esquire, at (713) 220-4323. 
 Please notify me immediately if any of the information disclosed in
your answers changes. Please answer all questions. Indicate “none” or “not applicable” when appropriate. Information should be given as of the date of this Questionnaire, even if previously reported to the Company. 
 IN ANSWERING THESE QUESTIONS, PLEASE REFER TO THE INSTRUCTIONS AT THE BEGINNING OF THIS QUESTIONNAIRE. 
  

					
	 Name of Selling Securityholder:
	 	  
	 	

  

 A-1 

 Instructions and Definitions 
 The following instructions and definitions are furnished to aid you in preparing your answers to this Questionnaire. 
  

	 	1.	For purposes of this Questionnaire the term “Company” means Flotek Industries, Inc. 

  

	 	2.	“Beneficial” ownership. Beneficial ownership shall have the meaning ascribed to it in Section 13(d) of the Securities Exchange Act of 1934, as
amended. The SEC has taken the position that if you have sole or shared voting power or dispositive power or the ability to acquire either sole or shared voting or dispositive power of a security within 60 days, you are the beneficial owner of that
security, even though that security is not registered in your name. Thus, for example, you could be the beneficial owner of securities in a trust or estate of which you are a trustee or executor, or of which you are one of the trustees or executors,
or you could be the beneficial owner of securities which you have a right to purchase. 

  

	 	3.	The term “affiliate” for purposes of this Questionnaire means any person directly or indirectly controlling, controlled by, or under common control with the
Selling Securityholder. 

  

 A-2 

	 	1.	Broker-Dealer Status. 

 (a) Are you, or are you an affiliate of, a broker-dealer registered under the Securities Exchange Act of 1934? 
 Yes                                      
                No               
 If “yes,” please give details below. 
 (b) Please confirm the following statement: The Company’s equity securities that are being issued to you were acquired in the ordinary course of your business, and at the time the securities were
issued to you, you did not have any agreement or understanding, directly or indirectly, with any person to distribute the securities. 
 Confirmed                      Cannot
Confirm               
 If “cannot
confirm,” please give details below. 
  

	 	2.	Relationships with the Company. 

 (a) Have you held any position or office with the Company, its predecessors or affiliates within the last three years? 
 Yes                                      
                No               
 If “yes,” please give details below. 
 (b) Have you had any other material relationship with the Company, its predecessors or affiliates within the last three years? 
 Yes                                      
                No               
 If “yes,” please give details below. 
  

 A-3 

	 	3.	Equity Securities Beneficially Owned By You. 

 (a) Please state the number and type of equity securities of the Company beneficially owned (please see instructions and definitions on page 2) by you as of the date of this Questionnaire, including
securities which are exercisable or convertible into equity securities within 60 days of the date of this Questionnaire. 
  

			
	 Class of Security
	  	Number of Shares Beneficially Owned
		  	

 (b) If any natural person or entity other than you holds or shares voting power or dispositive power
with respect to the Company’s equity securities listed in response to Question 3(a), please provide the names of the natural persons (including titles) or entities that hold or share such voting power or dispositive power and indicate the
number of the Company’s equity securities covered thereby. 
 (c) With respect to the Company’s equity securities
listed in response to Questions 3(a) and 3(b) for which an entity holds or shares voting power or dispositive power, please provide the names of the natural persons (including titles) or entities that control the entity or entities listed in
response to Questions 3(a) and 3(b). 
 (d) Please continue to list the natural persons or entities that control the
entities listed in response to Question 3(c) and the entities listed in response to this Question 3(d) until you have listed only natural persons (including titles) that control the applicable entity or entities. 
 (e) If any person or entity disclaims beneficial ownership of any of the equity securities you have listed in response to Question 3, please
so indicate: 
  

 A-4Consulting Agreement, Dr. Paul Bottomley

 Exhibit 10.16 
 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (this
“Agreement”) is made effective as of May 1, 2009, by and between SurgiVision, Inc., a Delaware corporation (the “Company”), and Dr. Paul Bottomley (“Consultant”). 
 The Company and Consultant hereby agree that Consultant will advise the Company on matters relating to the field of internal MRI coils
including advances in MRI hardware and software, in vivo and/or implantable MRI/RF safe probes, leads, electrodes, coils, catheters, and implantable interventional or diagnostic medical devices, such as implantable pulse generators, implantable
leads, neuromodulation and/or deep brain stimulation devices and related operational MRI compatible software and hardware (the “Field”), under the following terms and conditions: 
 1. Consulting Services. Consultant’s responsibilities shall include the following activities (collectively referred to as the
“Services”): 
 a) informing the Company of new developments in the Field, subject to the
provisions set forth in Section 2 below regarding non-disclosure under this Agreement; 
 b) advising the
Company on the Company’s research and development projects relating to the Field; 
 c) advising the Company
regarding development of prototype devices; 
 d) assisting with technical evaluation of the Company’s
methods, processes, devices, products and prototypes; 
 e) participating in scientific advisory committee
meetings in relation to the Field, as the Company may request, 
 f) timely disclosing to the Company patentable
ideas, conceptions, and/or inventions resulting from services rendered under this Agreement (“Inventions”), whether conceived or reduced to practice by Consultant alone or with employees or other advisors or consultants to Company,
and cooperating with the Company to prepare, file and prosecute patent applications for Inventions as are deemed necessary by the Company to publish or protect Inventions, by patent or otherwise, and to vest title to Inventions in the Company or its
nominees, their successors or assigns; and 
 g) cooperating with the Company to provide expert technical advice
based on Consultant’s know-how for commercializing products in the Field, upon reasonable request from Company. 
 The
Services shall be performed via telephone and correspondence and/or onsite at the Company’s facilities, and they may include meetings with personnel and other consultants at times and locations to be mutually agreed upon. In each instance,
Consultant shall perform the Services only upon Company’s request and after the scope of the Services has been approved by Company. 
  

 1 

 2. Consultant’s Obligations to JHU. The parties acknowledge that the Johns
Hopkins University, its Schools and Divisions, and the Johns Hopkins Hospital and Health System and its affiliated hospitals (“JHU”) is not a party to this Agreement, which is a private contract between Consultant and the Company.
Therefore, JHU shall have no liability under this Agreement. The office address of Consultant may be identified in this Agreement for the purpose of convenient communication between the Company and Consultant. Consultant shall not use the
facilities, equipment, materials, funds, or resources owned or administered by JHU or located on any of the premises of JHU, excluding those such materials, resources, or space that the Company is granted use of by JHU via formal institutional
transactions, including rent of incubator space, hourly charges to the Company by JHU for services, and the like. Consultant shall not engage or employ students, trainees, post-doctoral fellows or other employees of JHU to provide services under
this Agreement. JHU policies and Consultant’s obligations to JHU shall govern and be afforded primacy in the event a conflict arises between such obligations and policies in this Agreement. Consultant shall not disclose under this Agreement:
(a) any invention, improvement, or other information that is proprietary to JHU and not generally available to the public without permission from the Johns Hopkins Technology Transfer Office, other than through formal institutional
transactions; or (b) unpublished results of, or unpublished data from, research or clinical activity conducted at, by, or on behalf of JHU, except where said unpublished results or data are posted or made openly available to the scientific
community, for example via electronic means, web-sites, on-line methods, on-line courses, and the like or except with the permission of Johns Hopkins Technology Transfer Office. Nothing in this Agreement shall in any way inhibit Consultant’s
ability to conduct research and other academic activities at, through, or on behalf of JHU, or to lecture upon, submit for publication, publish, or otherwise disclose the results of such activities, regardless of the sponsor or field of such
activities, during or at any time after the term of this Agreement. 
 3. Confidentiality. “Confidential
Information” means all oral, written, graphic, or physical information, disclosed to Consultant under this Agreement, not generally available to the public, including without limitation, information related to Company’s products,
processes, techniques, technology, formulae, research data, manufacturing methods, know-how, and trade secrets. All Confidential Information is and will be the exclusive property of Company and its affiliates. Consultant agrees not to use
Confidential Information for any purposes other than the performance of the Services. Nothing in this Agreement shall limit or be construed to limit Consultant’s right to use, disseminate, or publish any information that: (a) is or becomes
available to the public through no breach of this Agreement by Consultant; (b) was or is obtained by Consultant from a third party who had the legal right to disclose the information to Consultant; (c) is already in the possession of
Consultant at the time it is communicated to Consultant under this Agreement (or any predecessor agreement hereto); (d) was developed by Consultant independently of and without reference to any information communicated to Consultant under this
Agreement (or any predecessor agreement hereto); or (e) is required to be disclosed by law, government regulation, or court order. 
 4. Speaking, Non-Endorsement, and Publications. Consultant and Company agree that Company will not use Consultant’s name or likeness for the purpose of endorsement,

  

 2 

 
promotion or marketing of the Company or its products. Consultant shall not under this Agreement speak with or to any third parties in any context or manner that could reasonably constitute
endorsement, promotion, or marketing of any product or technology. In speaking with or to any third parties or if citing Consultant in any context, format, or document, the following disclaimer must be presented: “Participation by
Dr. Bottomley [in the development of this product or as an advisor, consultant, speaker, or member of the Scientific Advisory Board] does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital
and Health System.” Consultant shall not publish, nor submit for publication, any work resulting from the Services provided hereunder without prior written approval from Company. If Consultant is listed as an author on any publication resulting
from performance of Services under this Agreement, the following form of acknowledgement must be added to the body of the publication: 
 a) If Consultant’s contributions to the work result wholly from the Services performed under this Agreement, Consultant’s position, address, and contact information will be listed as at the
Company, and JHU will not be mentioned in this reference (with the exception that, in the event that JHU’s name is included in the official mailing address of a biotechnology park and the Company’s premises are located therein, then
JHU’s name may be included as a legitimate mailing address); or 
 b) If Consultant’s contributions to
the work include materials arising out of both the Services performed under this Agreement and work done at JHU: “Dr. Bottomley is a paid consultant to SurgiVision, Inc. This arrangement has been approved by Johns Hopkins University in
accordance with its conflict of interest policies.” 
 5. No Conduct of Clinical Research. Consultant shall be
engaged by the Company to provide consulting services only as set forth in Section 1 above, and shall not direct or conduct clinical trials for or on behalf of the Company under this Agreement. Data provided to Consultant under this Agreement
will not include any identifying information regarding patients or human subjects and Consultant will not have access to this information, either directly or indirectly through coding systems that link de-identified data to individual persons.

 6. Ownership of Intellectual Property. All discoveries, inventions, improvements, or processes (whether patentable or
not) conceived or first reduced to practice by Consultant, whether alone or in collaboration with employees of or other consultants or advisors to the Company, resulting from the Services rendered under this Agreement will be owned exclusively by
the Company. Consultant shall assign to the Company all rights, title, and interest thereto and agrees to execute any documents attesting to the ownership thereof as requested by the Company. Consultant shall reasonably assist the Company in
obtaining or perfecting the Company’s rights, title, and interest, including, without limitation, the filing and prosecution of any patent applications. The Company shall have no rights under this Agreement to any publication, invention,
discovery, improvement, or other intellectual property whatsoever, whether or not publishable, patentable, or copyrightable, which is developed as a result of a program of research a) financed in whole or in part by funds provided by or under the
control of JHU, or b) using the facilities, resources, or employees of JHU (which for this purpose does not include any materials, resources, or space that the Company is granted use of by JHU via formal institutional transactions, including rent of
incubator space, hourly charges to the Company by JHU for services, and the like). 
  

 3 

 7. Compensation. In consideration for Consultant’s Services hereunder, the
Company shall pay Consultant as follows: 
 a) $60,000 per year, payable in equal monthly installments; and

 b) Reasonable out-of-pocket expenses (upon presentation of appropriate receipts) incurred by Consultant,
including all travel, food and lodging in connection with the Services provided hereunder. 
 Payment shall be made within
forty-five (45) days of receipt of an invoice of itemized services and submission of appropriate vouchers and receipts as may be reasonably necessary to substantiate Consultant’s out-of-pocket expenses. 
 Consultant shall not be paid vacation, holiday, or sick time during the term of the Agreement. In the event of premature termination of this
Agreement, the Company shall pay Consultant for the Services performed and expenses incurred through the date of termination. In the event of any overpayment by the Company, Consultant shall, upon submission by the Company of documents evidencing
such overpayment, remit the same to the Company within thirty (30) days after termination. Consultant shall also cooperate with Company in producing documents as evidence of overpayment of either party. 
 8. Term and Termination. This Agreement shall be effective for a period of twenty-four (24) months, beginning May 1, 2009
and ending April 30, 2011. 
 This Agreement may be extended by written agreement signed by both parties. Either party may
terminate this Agreement with or without cause upon giving thirty (30) days prior written notice to the other party. Termination or expiration of this Agreement shall not affect any rights or obligations which have accrued prior thereto or in
connection therewith. Any written agreements altering the term and/or conditions of this agreement may be subject to advance review and approval by the Johns Hopkins University School of Medicine’s Office of Policy Coordination. 
 9. Compliance. In the performance of the Services hereunder, Consultant shall comply with all applicable federal, state, and local
laws, regulations, and guidelines. Consultant shall also comply with the Company’s policies while on the Company premises. 
 10. Independent Contractor. Consultant’s status under this Agreement is that of an independent contractor. Consultant shall not be deemed an employee, agent, partner, or joint venturer of the Company for any purpose whatsoever,
and Consultant shall have no authority to bind or act on behalf of the Company. This Agreement shall not entitle Consultant to participate in any benefit plan or program of Company. Consultant shall be responsible for, and agrees to comply with,
obligations under federal and state tax laws for payment of income and, if applicable, self-employment tax. 
  

 4 

 11. Assignment. Consultant may not assign this Agreement or any interest herein, or
delegate any of his duties hereunder, to any third party without the Company’s prior written consent, which consent is within the Company’s sole discretion to grant or withhold. Any attempted assignment or delegation by Consultant without
such consent shall be null and void. 
 12. Debarment. Consultant warrants and represents that Consultant has never been,
is not currently, and during the term of this Agreement, will not become: 
 a) an individual who has been
debarred by the U.S. Food and Drug Administration (“FDA”) pursuant to 21 U.S.C. 335a (a) or (b) (“Debarred Individual”) from providing services in any capacity to a person that has an approved or pending
drug product application, or an employer, employee or partner of a Debarred Individual; or 
 b) a corporation,
partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. 335a (a) or (b) (“Debarred Entity”) from submitting or assisting in the submission of any abbreviated drug application, or an employee, partner,
shareholder, member, subsidiary or affiliate of a Debarred Entity. 
 Consultant further warrants and represents that no
Debarred Individual or Debarred Entity has performed or rendered, or will perform or ender, any services or assistance relating to activities taken pursuant to this Agreement. Consultant further warrants and represents that Consultant has no
knowledge of any circumstances which may affect the accuracy of the foregoing warranties and representations, including, but not limited to, FDA investigation of, or debarment proceedings against Consultant or any person or entity performing
services or rendering assistance relating to activities taken pursuant to this Agreement, and Consultant will immediately notify the Company if Consultant becomes aware of any such circumstances during the term of this Agreement. 
 13. Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the matters herein contained
and supersedes all previous agreements and undertakings with respect thereto. This agreement may be modified only by written agreement signed by the parties. 
 This Agreement shall be governed by and construed in accordance with the laws of the State of Maryland without regard to its conflicts of laws rules. 
 [The next page is the signature page] 
 *** 
  

 5 

 IN WITNESS WHEREOF, the parties have executed this Consulting Agreement as of the date(s)
set forth below, but with an effective date as of May 1, 2009. 
  

			
	COMPANY:
	
	SurgiVision, Inc.
		
	By:	 	
 

	Name:	 	 OSCAR THOMAS

	Title:	 	 Vice President, Business Affairs

		
	Date:	 	 October 13, 2009

	
	Address:
	One Commerce Square
	Suite 2550
	Memphis, TN 38103
	
	CONSULTANT:
	
	
 

	Dr. Paul Bottomley
		
	Date:	 	 Tuesday, October 13, 2009

	
	Address:
	
	             6308 Velvet Path

	
	             Columbia, MD 21044

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]